JP2008520719A5 - - Google Patents

Download PDF

Info

Publication number
JP2008520719A5
JP2008520719A5 JP2007543334A JP2007543334A JP2008520719A5 JP 2008520719 A5 JP2008520719 A5 JP 2008520719A5 JP 2007543334 A JP2007543334 A JP 2007543334A JP 2007543334 A JP2007543334 A JP 2007543334A JP 2008520719 A5 JP2008520719 A5 JP 2008520719A5
Authority
JP
Japan
Prior art keywords
alkylamino
hydrogen
aryl
alkoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007543334A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520719A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/042095 external-priority patent/WO2006057946A2/en
Publication of JP2008520719A publication Critical patent/JP2008520719A/ja
Publication of JP2008520719A5 publication Critical patent/JP2008520719A5/ja
Withdrawn legal-status Critical Current

Links

JP2007543334A 2004-11-22 2005-11-17 チューブリン結合抗癌剤およびそれらのプロドラッグ Withdrawn JP2008520719A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63042204P 2004-11-22 2004-11-22
US72692805P 2005-10-14 2005-10-14
PCT/US2005/042095 WO2006057946A2 (en) 2004-11-22 2005-11-17 Tubulin binding anti cancer agents and prodrugs thereof

Publications (2)

Publication Number Publication Date
JP2008520719A JP2008520719A (ja) 2008-06-19
JP2008520719A5 true JP2008520719A5 (enExample) 2009-01-22

Family

ID=36498450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543334A Withdrawn JP2008520719A (ja) 2004-11-22 2005-11-17 チューブリン結合抗癌剤およびそれらのプロドラッグ

Country Status (10)

Country Link
US (1) US20090042820A1 (enExample)
EP (1) EP1819338A4 (enExample)
JP (1) JP2008520719A (enExample)
KR (1) KR20070086595A (enExample)
AU (1) AU2005309761A1 (enExample)
CA (1) CA2587210A1 (enExample)
IL (1) IL183212A0 (enExample)
MX (1) MX2007006102A (enExample)
NO (1) NO20073211L (enExample)
WO (1) WO2006057946A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
CN102746336B (zh) 2005-06-29 2015-08-19 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物
KR20090025367A (ko) * 2006-06-28 2009-03-10 가부시키가이샤산와카가쿠켄큐쇼 신규 6-5계 이환식 복소환 유도체 및 그 의약용도
EP2114157B1 (en) 2006-12-26 2021-05-26 ImmunoGenesis, Inc. Phosphoramidate alkylator prodrug for the treatment of cancer
US8765690B2 (en) 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
WO2008151253A1 (en) * 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
WO2010048330A1 (en) 2008-10-21 2010-04-29 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs
FR2962437B1 (fr) * 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
US9487506B2 (en) 2011-04-13 2016-11-08 Merck Sharp & Dohme Corp. Mineralocorticoid receptor antagonists
WO2014069063A1 (ja) 2012-10-29 2014-05-08 京セラ株式会社 弾性表面波センサ
CA2924843A1 (en) * 2013-09-27 2015-04-02 Allergan, Inc. Compounds and methods for skin repair
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
PE20161573A1 (es) 2014-02-13 2017-01-19 Incyte Corp Ciclopropilamina como inhibidor de la lsd1
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
CN107530556B (zh) 2015-03-10 2020-04-10 深圳艾欣达伟医药科技有限公司 Dna烷化剂
US10829437B2 (en) * 2015-04-02 2020-11-10 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
CA2990665A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
CN109414410B (zh) 2016-04-22 2022-08-12 因赛特公司 Lsd1抑制剂的制剂
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
US11427591B2 (en) 2018-10-17 2022-08-30 Insilico Medicine Ip Limited Kinase inhibitors
CN115403483B (zh) * 2021-07-02 2024-01-26 河南省儿童医院郑州儿童医院 含二苯乙烯或二苯甲酮骨架的ca-4衍生物、药物组合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099139A1 (en) * 2000-09-15 2004-11-18 Baylor University Indole-containing compounds with anti-tubulin and vascular targeting activity
DE60129536T2 (de) * 2000-03-10 2008-06-19 Baylor University, Waco Tubulin bindende liganden
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2839718B1 (fr) * 2002-05-17 2004-06-25 Sanofi Synthelabo Derives d'indole, leur procede de preparation et les compositions pharmaceutiques en contenant
DE60336646D1 (de) * 2003-08-07 2011-05-19 Nat Health Research Institutes Indol-Verbindungen als Inhibitoren der Tubulin-Polymerisation zur Behandlung von angiogenesisbezogenen Erkrankungen
US7456289B2 (en) * 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds

Similar Documents

Publication Publication Date Title
JP2008520719A5 (enExample)
JP2020505376A5 (enExample)
RU2019126455A (ru) Пиридиновые соединения в качестве аллостерических ингибиторов shp2
JP2018109017A5 (enExample)
KR20180105700A (ko) 체크포인트 키나아제 1(chk1) 억제제로서 유용한 3,5-이치환된 피라졸, 및 이의 제조 및 적용
JP2001504109A (ja) ベンゾ複素環ジスタマイシン誘導体、それらを製造する方法および抗腫瘍および抗ウイルス剤としてのそれらの用途
RU2010137115A (ru) Производные 5,6-бисарил-2-пиридинкарбоксамидов, способ их получения и их применение в терапии в качестве антагонистов рецепторов
RU2012102922A (ru) Лекарственные соединения и композиции
JP2017519754A5 (enExample)
JP2015522551A5 (enExample)
EA030569B1 (ru) Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофильной эластазы
JP2018513832A5 (enExample)
JP2010520168A5 (enExample)
JPH03170482A (ja) 3環性プテリジノン類及びその製造方法
BR112014023957B1 (pt) Compostos agonistas dos receptores adrenérgicos alfa-2 e composição farmacêutica que compreende os mesmos
JP2015502371A5 (enExample)
UA61922C2 (uk) Акрилоїлзаміщенa похідна дистаміцину, спосіб її одержання (варіанти) та фармацевтична композиція на її основі
CA2931804A1 (en) Piperidine and piperazine derivatives and their use in treating viral infections and cancer
KR20130121857A (ko) 다발성 골수종의 치료 효과를 갖는 피라졸 화합물
EP4201941B1 (en) Pyrazole boronic acid compound, pharmaceutical composition containing same, and uses thereof
EP2154139A1 (en) Bicyclic heterocyclic compound
EP2632916B1 (en) Novel anti-cancer agents
DK2991993T3 (en) NEW MORPHOLINYLANTHRACYCLINE DERIVATIVES
JPH07196511A (ja) キノキサリンおよびヌクレオシドを含有する複合製剤
WO2006010594A1 (en) Inhibitors of hsp90